Status:
WITHDRAWN
Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Lead Sponsor:
University of California, San Diego
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Hereditary Hemorrhagic Telangiectasia (HHT)
Nosebleeds
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study is for patients with recurrent epistaxis (nosebleeds) as a result of Hereditary Hemorrhagic Telangiectasia (HHT). The aim is to determine if ranibizumab, topically applied will diminish epi...
Detailed Description
This is an open-label, Phase I study of intranasal administered ranibizumab in subjects with HHT. Plans are to recruit patients with HHT from the UCSD Nasal Dysfunction Clinic. Those who come for eva...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Subjects will be eligible if the following criteria are met:
- Ability to provide written informed consent and comply with study assessments for the full duration of the study
- Age \> 18 years
- Diagnosed with HHT
- Deemed appropriate for topical Ranibizumab without laser, as determined by severity. For the Ranibizumab to be effective, the spray needs to reach the nasal mucosa. Patients will be instructed in nasal irrigation and will only be treated if they can keep their noses clean.
- Severe patients will presumably not achieve this goal, so subjects will be patients with moderate disease as defined by the epistaxis severity score sheet (Appendix B)
- Exclusion Criteria
- Subjects who meet any of the following criteria will be excluded from this study:
- Coagulopathy
- Pregnancy (positive pregnancy test) or lactation
- Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch
- Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
- Participation in another simultaneous medical investigation or trial
- Patients who have had bevacizumab therapy, injection, or spray
- Patients with a known reaction based on macular degeneration treatment
- Patients having received VEGF inhibitors in the last 2 years for the treatment of any ophthalmologic disease
Exclusion
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2012
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01406639
Start Date
July 1 2011
End Date
May 1 2012
Last Update
April 29 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.